Home > Resources > Whitepapers > Long-term follow-up studies of cell and gene therapies

Cell and Gene Therapy

Long-term follow-up studies of cell and gene therapies

September 29, 2022

The market is experiencing a surge in the availability
of cell and gene therapies (CGTs); it’s estimated that
by 2025 as many as 20 will be introduced into the US
each year.1,2

Spotlight

Collagen Solutions plc

Collagen Solutions Plc (AIM:COS) is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and other biomaterials for use in regenerative medicine, medical devices and in-vitro diagnostics and research.

OTHER WHITEPAPERS

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Synthetic Biology Biotechnology and AgTech

whitePaper | March 12, 2022

CRISPR, gene editing, biotech, precision agriculture and automation influencing the future of business, government, food, medicine, geopolitics and society

A New Generation of Cancer Immunotherapies

whitePaper | June 9, 2022

Despite recent progress in fighting cancer the sad reality is that it remains a leading cause of morbidity and mortality. Some of the most promising new treatments have emerged from the convergence of the oncology and immunology fields.